In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ikano Therapeutics, Inc.

Latest From Ikano Therapeutics, Inc.

Mérieux and Shire funds back NeuroPhage in $12.4 million round for Alzheimer's

NeuroPhage Pharmaceuticals, a privately held company based in Cambridge, Massachusetts, has been quietly advancing novel approaches to the treatment of neurodegenerative diseases, and now has gained attention by landing $12.4 million in new venture funding. It will use the funds to begin preparations for a Phase I trial of its lead candidate to treat Alzheimer's disease, NPT001, which disaggregates existing beta amyloid plaques.

Neurology Israel

New appointment at Palatin Technologies

Palatin Technologies has appointed Dr Jeffrey Edelson chief medical officer. He has more than 15 years' leadership experience in the clinical development of medicines for the pharmaceutical and biotech industries, having previously served as executive vice-president of R&D and chief medical officer of Ikano Therapeutics.


Deals Shaping the Medical Industry (09/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Mind over matter - the novel and the new: anticonvulsants

Despite a generally low level of innovation in the anticonvulsant sector, there are some novel products in the pipeline. We look at some of the candidates nearing the market.

Neurology Puerto Rico
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Nasal
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Intranasal Therapeutics, Inc.